Alnylam Grants Dharmacon License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market
Advertisement
Alnylam Pharmaceuticals, Inc. and Dharmacon, Inc., a business unit of the Fisher Biosciences group, announced that Alnylam has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned solely by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
Alnylam's intellectual property estate includes certain "fundamental" patents and patent applications that claim broad structural and functional properties of synthetic RNAi products. This fundamental intellectual property includes the Kreutzer-Limmer patent family that was obtained through the July 2003 acquisition of Ribopharma AG, now Alnylam Europe AG. The Kreutzer-Limmer family includes: EP Patent No. 1144623, covering siRNAs up to 25 nucleotides in length having a sequence complementary to a target gene; and EP Patent No. 1214945, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides. Patents corresponding to these European patents have been issued or are pending in many other countries.
Other news from the department research and development
These products might interest you
Most read news
More news from our other portals
Last viewed contents
NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership - Establishing whole genome sequencing centre in Singapore
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome - Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study
Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million - "This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Risk of lead poisoning from urban gardening is low, new study finds
World first: Launch of Quebec registry for users of medical cannabis - MUHC researcher heads one of the largest studies ever conducted on medical cannabis
Implant-based cancer vaccine is first to eliminate tumors in mice - New approach reprograms the mammalian immune system to attack tumors body-wide
Study IDs link between sugar signaling and regulation of oil production in plants
It all adds up: Study finds forever chemicals are more toxic as mixtures - Research also finds that PFOA and PFOS are major contributors to toxicity
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
‘Seaweed drug’ helps fight off infection - Alginates found in seaweed can combat multi-drug resistant infections
